Linked Life Data

21098232

Source:http://linkedlifedata.com/resource/pubmed/id/21098232

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-12-3
pubmed:abstractText
Protein-in-adjuvant formulations and viral-vectored vaccines encoding blood-stage malaria Ags have shown efficacy in rodent malaria models and in vitro assays against Plasmodium falciparum. Abs and CD4(+) T cell responses are associated with protective efficacy against blood-stage malaria, whereas CD8(+) T cells against some classical blood-stage Ags can also have a protective effect against liver-stage parasites. No subunit vaccine strategy alone has generated demonstrable high-level efficacy against blood-stage infection in clinical trials. The induction of high-level Ab responses, as well as potent T and B cell effector and memory populations, is likely to be essential to achieve immediate and sustained protective efficacy in humans. This study describes in detail the immunogenicity of vaccines against P. falciparum apical membrane Ag 1 in rhesus macaques (Macaca mulatta), including the chimpanzee adenovirus 63 (AdCh63), the poxvirus modified vaccinia virus Ankara (MVA), and protein vaccines formulated in Alhydrogel or CoVaccine HT adjuvants. AdCh63-MVA heterologous prime-boost immunization induces strong and long-lasting multifunctional CD8(+) and CD4(+) T cell responses that exhibit a central memory-like phenotype. Three-shot (AdCh63-MVA-protein) or two-shot (AdCh63-protein) regimens induce memory B cells and high-titer functional IgG responses that inhibit the growth of two divergent strains of P. falciparum in vitro. Prior immunization with adenoviral vectors of alternative human or simian serotype does not affect the immunogenicity of the AdCh63 apical membrane Ag 1 vaccine. These data encourage the further clinical development and coadministration of protein and viral vector vaccine platforms in an attempt to induce broad cellular and humoral immune responses against blood-stage malaria Ags in humans.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1550-6606
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
185
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7583-95
pubmed:meshHeading
pubmed-meshheading:21098232-Adenoviridae, pubmed-meshheading:21098232-Adjuvants, Immunologic, pubmed-meshheading:21098232-Animals, pubmed-meshheading:21098232-Antibodies, Protozoan, pubmed-meshheading:21098232-Antigens, Protozoan, pubmed-meshheading:21098232-B-Lymphocytes, pubmed-meshheading:21098232-CD4-Positive T-Lymphocytes, pubmed-meshheading:21098232-Humans, pubmed-meshheading:21098232-Immunity, Cellular, pubmed-meshheading:21098232-Immunity, Humoral, pubmed-meshheading:21098232-Immunoglobulin G, pubmed-meshheading:21098232-Immunologic Memory, pubmed-meshheading:21098232-Macaca mulatta, pubmed-meshheading:21098232-Malaria, Falciparum, pubmed-meshheading:21098232-Malaria Vaccines, pubmed-meshheading:21098232-Membrane Proteins, pubmed-meshheading:21098232-Mice, pubmed-meshheading:21098232-Plasmodium falciparum, pubmed-meshheading:21098232-Poxviridae, pubmed-meshheading:21098232-Protozoan Proteins, pubmed-meshheading:21098232-Vaccines, Subunit, pubmed-meshheading:21098232-Vaccinia virus
pubmed:year
2010
pubmed:articleTitle
Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
pubmed:affiliation
Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom. simon.draper@ndm.ox.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't